ZURICH, May 21 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) said on Monday it had filed a single-tablet combination of its Tekturna high blood pressure drug and a diuretic for U.S. approval.
New clinical data, to be presented on Monday in Chicago, shows Tekturna significantly lowers blood pressure over a one-year period, both alone and in combination with the widely-used diuretic hydrochlorothiazide, Novartis said.
WASHINGTON (Reuters) - Last week's failed plot to bomb a U.S. passenger jet has exposed lingering fissures within the U.S. intelligence community, which had information from interviews and clandestine intercepts but did not put the pieces together, officials said.
A spectacular credit bust, two devastating stock market crashes ... the smart call this decade was to play it safe. Full Article
Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
